Biotech firm AIVITA Biomedical has completed patient enrolment in a Phase II clinical trial of AV-GBM-1 for the treatment of glioblastoma.

AV-GBM-1 is an investigational immunotherapy designed to target autologous tumour-initiating cells associated with the growth and proliferation of cancer.

The immunotherapy is said to require short-term cell culture and a successful leukapheresis for the production of the final treatment product.

In the eight-site, single-arm Phase II trial, the company is assessing the clinical efficacy of the drug candidate as a monotherapy and in combination with PD-1 inhibitors in around 55 patients.

The primary endpoint of the study is overall survival. The company also intends to develop the therapy as a maintenance treatment to address recurrence.

AIVITA Biomedical chief medical officer Bob Dillman said: “An extremely high manufacturing success rate combined with a very low cost of goods makes this approach highly desirable from both a clinical and commercial viability perspective.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We’re already exploring new ways to further increase efficiency and expand the applicability of this approach.”

The company is currently performing two other trials of its platform immunotherapy in the US.

The Phase II double-blind trial is enrolling 99 ovarian patients who will be given the autologous tumour-initiating immunotherapy or autologous monocytes.

Meanwhile, an open-label, single-arm Phase Ib study is being conducted to investigate the safety of administering the tumour-initiating immunotherapy plus anti-PD1 monoclonal antibodies in treating metastatic melanoma. This trial study is designed for 14-20 patients and is yet to begin enrolment.

AIVITA secured US Food and Drug Administration (FDA) approval earlier this month to conduct the Phase Ib study.

In addition, the company is working to obtain conditional commercial approval for its melanoma treatment in Japan.